SAR 441566
Alternative Names: SAR-441566Latest Information Update: 28 May 2024
At a glance
- Originator Sanofi
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Psoriasis; Rheumatoid arthritis
- No development reported Inflammation
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in France (PO)
- 10 Nov 2023 Pharmacodynamics and adverse events data from a phase-I clinical trials presented at the ACR Convergence 2023 (ACR-ARP-2023)
- 07 Nov 2023 Phase-II clinical trials in Rheumatoid arthritis in Canada, USA (PO, Tablet) (NCT06073093)